Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Autolus Therapeutics PLC Sponsored ADR stock logo
AUTL
Autolus Therapeutics
$2.43
+0.8%
$2.04
$1.11
$5.00
$641.40M1.811.57 million shs1.39 million shs
Relay Therapeutics, Inc. stock logo
RLAY
Relay Therapeutics
$3.63
+3.7%
$3.27
$1.78
$10.72
$600.06M1.622.10 million shs2.15 million shs
SNDL Inc. stock logo
SNDL
SNDL
$1.58
+2.6%
$1.32
$1.15
$2.40
$404.67M3.41.96 million shs2.07 million shs
Instil Bio, Inc. stock logo
TIL
Instil Bio
$27.62
+5.8%
$25.64
$9.85
$92.00
$171.19M2.15199,101 shs183,125 shs
7 Energy Stocks to Buy and Hold Forever Cover

With the proliferation of data centers and electric vehicles, the electric grid will only get more strained. Download this report to learn how energy stocks can play a role in your portfolio as the global demand for energy continues to grow.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Autolus Therapeutics PLC Sponsored ADR stock logo
AUTL
Autolus Therapeutics
0.00%-2.43%+17.56%+67.36%-43.29%
Relay Therapeutics, Inc. stock logo
RLAY
Relay Therapeutics
0.00%-2.78%+9.72%+27.27%-59.30%
SNDL Inc. stock logo
SNDL
SNDL
0.00%+10.79%+23.20%+13.24%-25.60%
Instil Bio, Inc. stock logo
TIL
Instil Bio
0.00%+6.57%-5.78%+63.13%+106.32%
CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Autolus Therapeutics PLC Sponsored ADR stock logo
AUTL
Autolus Therapeutics
2.6893 of 5 stars
3.51.00.00.02.53.30.6
Relay Therapeutics, Inc. stock logo
RLAY
Relay Therapeutics
2.6522 of 5 stars
3.41.00.00.03.42.50.6
SNDL Inc. stock logo
SNDL
SNDL
1.2682 of 5 stars
2.03.00.00.00.60.01.3
Instil Bio, Inc. stock logo
TIL
Instil Bio
2.3948 of 5 stars
3.52.00.00.00.63.30.6
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Autolus Therapeutics PLC Sponsored ADR stock logo
AUTL
Autolus Therapeutics
3.00
Buy$9.32283.54% Upside
Relay Therapeutics, Inc. stock logo
RLAY
Relay Therapeutics
2.83
Moderate Buy$17.67386.69% Upside
SNDL Inc. stock logo
SNDL
SNDL
0.00
N/A$4.00153.16% Upside
Instil Bio, Inc. stock logo
TIL
Instil Bio
3.00
Buy$119.00330.85% Upside

Current Analyst Ratings Breakdown

Latest TIL, SNDL, AUTL, and RLAY Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
7/21/2025
Autolus Therapeutics PLC Sponsored ADR stock logo
AUTL
Autolus Therapeutics
Needham & Company LLC
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$10.00
6/12/2025
Autolus Therapeutics PLC Sponsored ADR stock logo
AUTL
Autolus Therapeutics
Needham & Company LLC
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$10.00
6/5/2025
Instil Bio, Inc. stock logo
TIL
Instil Bio
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$125.00 ➝ $125.00
6/2/2025
Instil Bio, Inc. stock logo
TIL
Instil Bio
JMP Securities
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingMarket Perform ➝ Market Perform
5/22/2025
Instil Bio, Inc. stock logo
TIL
Instil Bio
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetBuy ➝ Buy$110.00 ➝ $105.00
5/7/2025
Relay Therapeutics, Inc. stock logo
RLAY
Relay Therapeutics
Guggenheim
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetBuy ➝ Buy$30.00 ➝ $10.00
(Data available from 7/21/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Autolus Therapeutics PLC Sponsored ADR stock logo
AUTL
Autolus Therapeutics
$10.12M63.91N/AN/A$1.61 per share1.51
Relay Therapeutics, Inc. stock logo
RLAY
Relay Therapeutics
$10.01M62.17N/AN/A$4.65 per share0.78
SNDL Inc. stock logo
SNDL
SNDL
$671.81M0.62N/AN/A$3.15 per share0.50
Instil Bio, Inc. stock logo
TIL
Instil Bio
N/AN/AN/AN/A$25.96 per shareN/A
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Autolus Therapeutics PLC Sponsored ADR stock logo
AUTL
Autolus Therapeutics
-$220.66M-$0.88N/AN/AN/AN/A-52.82%-29.67%8/14/2025 (Estimated)
Relay Therapeutics, Inc. stock logo
RLAY
Relay Therapeutics
-$337.71M-$2.23N/AN/AN/AN/A-44.17%-39.53%8/5/2025 (Estimated)
SNDL Inc. stock logo
SNDL
SNDL
-$69.18M-$0.29N/AN/AN/A-11.48%-9.02%-7.60%7/31/2025 (Estimated)
Instil Bio, Inc. stock logo
TIL
Instil Bio
-$74.14M-$11.97N/AN/AN/AN/A-45.52%-29.23%8/12/2025 (Estimated)

Latest TIL, SNDL, AUTL, and RLAY Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
8/14/2025Q2 2025
Autolus Therapeutics PLC Sponsored ADR stock logo
AUTL
Autolus Therapeutics
-$0.2329N/AN/AN/A$12.92 millionN/A
8/12/2025N/A
Instil Bio, Inc. stock logo
TIL
Instil Bio
-$1.72N/AN/AN/AN/AN/A
8/5/2025Q2 2025
Relay Therapeutics, Inc. stock logo
RLAY
Relay Therapeutics
-$0.49N/AN/AN/A$0.07 millionN/A
7/31/2025Q2 2025
SNDL Inc. stock logo
SNDL
SNDL
-$0.04N/AN/AN/A$231.50 millionN/A
5/13/2025Q1 2025
Instil Bio, Inc. stock logo
TIL
Instil Bio
-$2.02-$4.32-$2.30-$4.32N/AN/A
5/8/2025Q1 2025
Autolus Therapeutics PLC Sponsored ADR stock logo
AUTL
Autolus Therapeutics
-$0.24-$0.26-$0.02-$0.26$1.59 million$8.98 million
5/5/2025Q1 2025
Relay Therapeutics, Inc. stock logo
RLAY
Relay Therapeutics
-$0.50-$0.46+$0.04-$0.46$0.01 million$7.68 million
5/1/2025Q1 2025
SNDL Inc. stock logo
SNDL
SNDL
-$0.06-$0.04+$0.02-$0.04$214.60 million$142.38 million
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Autolus Therapeutics PLC Sponsored ADR stock logo
AUTL
Autolus Therapeutics
N/AN/AN/AN/AN/A
Relay Therapeutics, Inc. stock logo
RLAY
Relay Therapeutics
N/AN/AN/AN/AN/A
SNDL Inc. stock logo
SNDL
SNDL
N/AN/AN/AN/AN/A
Instil Bio, Inc. stock logo
TIL
Instil Bio
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Autolus Therapeutics PLC Sponsored ADR stock logo
AUTL
Autolus Therapeutics
N/A
9.24
9.02
Relay Therapeutics, Inc. stock logo
RLAY
Relay Therapeutics
N/A
19.96
19.96
SNDL Inc. stock logo
SNDL
SNDL
0.10
4.62
3.12
Instil Bio, Inc. stock logo
TIL
Instil Bio
0.58
30.33
30.33

Institutional Ownership

CompanyInstitutional Ownership
Autolus Therapeutics PLC Sponsored ADR stock logo
AUTL
Autolus Therapeutics
72.83%
Relay Therapeutics, Inc. stock logo
RLAY
Relay Therapeutics
96.98%
SNDL Inc. stock logo
SNDL
SNDL
N/A
Instil Bio, Inc. stock logo
TIL
Instil Bio
60.56%

Insider Ownership

CompanyInsider Ownership
Autolus Therapeutics PLC Sponsored ADR stock logo
AUTL
Autolus Therapeutics
25.70%
Relay Therapeutics, Inc. stock logo
RLAY
Relay Therapeutics
4.32%
SNDL Inc. stock logo
SNDL
SNDL
N/A
Instil Bio, Inc. stock logo
TIL
Instil Bio
47.20%
CompanyEmployeesShares OutstandingFree FloatOptionable
Autolus Therapeutics PLC Sponsored ADR stock logo
AUTL
Autolus Therapeutics
330266.14 million197.74 millionOptionable
Relay Therapeutics, Inc. stock logo
RLAY
Relay Therapeutics
330171.45 million164.04 millionOptionable
SNDL Inc. stock logo
SNDL
SNDL
2,516262.78 millionN/AOptionable
Instil Bio, Inc. stock logo
TIL
Instil Bio
4106.56 million3.51 millionNo Data

Recent News About These Companies

Instil Bio appoints new Chief Medical Officer

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All Headlines
Autolus Therapeutics stock logo

Autolus Therapeutics NASDAQ:AUTL

$2.43 +0.02 (+0.83%)
Closing price 04:00 PM Eastern
Extended Trading
$2.44 +0.01 (+0.45%)
As of 07:57 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Autolus Therapeutics plc, a clinical-stage biopharmaceutical company, develops T cell therapies for the treatment of cancer and autoimmune diseases. The company's clinical-stage programs include obecabtagene autoleucel (AUTO1), a CD19-targeting programmed T cell investigational therapy that is in Phase 1b/2 clinical trial for the treatment of adult ALL; AUTO1/22, which is in a Phase 1 clinical trial in pediatric patients with relapsed or refractory ALL; AUTO4, a programmed T cell investigational therapy for the treatment of peripheral T-cell lymphoma targeting TRBC1 and TRBC2; AUTO6NG, a programmed T cell investigational therapy targeting GD2 in development for the treatment of neuroblastoma; and AUTO8, a product candidate to treat multiple myeloma. It focuses on developing AUTO5, a preclinical TRBC2 programmed T cell product candidate for the treatment of peripheral T-cell lymphoma. Autolus Therapeutics plc was incorporated in 2014 and is headquartered in London, the United Kingdom.

Relay Therapeutics stock logo

Relay Therapeutics NASDAQ:RLAY

$3.63 +0.13 (+3.71%)
Closing price 04:00 PM Eastern
Extended Trading
$3.66 +0.04 (+0.96%)
As of 07:47 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Relay Therapeutics, Inc. operates as a clinical-stage precision medicines company. It engages in transforming the drug discovery process with an initial focus on enhancing small molecule therapeutic discovery in targeted oncology and genetic disease indications. The company's lead product candidates include RLY-4008, an oral small molecule inhibitor of fibroblast growth factor receptor 2 (FGFR2), which is in a first-in-human clinical trial for patients with advanced or metastatic FGFR2-altered solid tumors; RLY-2608, a lead mutant-PI3Ka inhibitor program that targets phosphoinostide 3 kinase alpha; and Migoprotafib (GDC-1971), an oral, small molecule, potent and selective inhibitor of the protein tyrosine phosphatase SHP2 that binds and stabilizes Src homology region 2 domain-containing phosphatase-2 (SHP2) as a monotherapy in patients with advanced or metastatic solid tumors. In addition, it has collaboration and license agreements with D. E. Shaw Research, LLC to research certain biological targets through the use of D. E. Shaw Research computational modeling capabilities focused on analysis of protein motion to develop and commercialize compounds and products directed to such targets; and Genentech, Inc. for the development and commercialization of GDC-1971. The company was formerly known as Allostery, Inc. and changed its name to Relay Therapeutics, Inc. in December 2015. Relay Therapeutics, Inc. was incorporated in 2015 and is headquartered in Cambridge, Massachusetts.

SNDL stock logo

SNDL NASDAQ:SNDL

$1.58 +0.04 (+2.60%)
Closing price 04:00 PM Eastern
Extended Trading
$1.58 +0.00 (+0.32%)
As of 07:57 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

SNDL Inc. engages in the production, distribution, and sale of cannabis products in Canada. The company operates through Liquor Retail, Cannabis Retail, Cannabis Operations, and Investments segments. It engages in the cultivation, distribution, and sale of cannabis for the adult-use and medical markets; sells wines, beers, and spirits through wholly owned liquor stores; and private sale of recreational cannabis through wholly owned and franchised retail cannabis stores. In addition, the company produces and distributes inhalable products, such as flower, pre-rolls, and vapes. It offers its products under the Top Leaf, Sundial Cannabis, Palmetto, and Grasslands brands. The company was formerly known as Sundial Growers Inc. and changed its name to SNDL Inc. in July 2022. SNDL Inc. was incorporated in 2006 and is headquartered in Calgary, Canada.

Instil Bio stock logo

Instil Bio NASDAQ:TIL

$27.62 +1.52 (+5.82%)
Closing price 04:00 PM Eastern
Extended Trading
$27.34 -0.29 (-1.03%)
As of 05:13 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Instil Bio, Inc., a clinical-stage biopharmaceutical company, focuses on developing a pipeline of novel therapies. The company develops cell therapy of tumor infiltrating lymphocyte (TIL) for the treatment of cancer. It is developing early-stage pipeline of CoStAR-TIL and other novel TIL technologies. Instil Bio, Inc. was incorporated in 2018 and is headquartered in Dallas, Texas.